Abstract | BACKGROUND: Administration of streptozotocin (STZ) at a 21-day interval has been described in dogs with stage II and III insulinoma. Myelosuppression was not observed, suggesting the possibility of increasing dose intensity by decreasing the interval between doses. OBJECTIVE: To describe the tolerability of a biweekly STZ protocol. A secondary objective was to describe the outcome of dogs treated with this protocol. ANIMALS: Nineteen dogs with residual local, metastatic, or recurrent insulinoma. METHODS: After surgery for insulinoma, or at the time of recurrence, dogs were treated with a previously described STZ and saline diuresis protocol. Treatments were administered every 14 days. All dogs received antiemetic treatment. Adverse events (AEs) were recorded and graded. Outcome endpoints assessed were progression-free survival (PFS) and survival. RESULTS: CONCLUSIONS AND CLINICAL IMPORTANCE:
Streptozotocin can be safely administered to dogs with insulinoma, but serious AEs are possible. Additional investigation is required to better define the role of STZ in managing dogs with insulinoma.
|
Authors | N C Northrup, K M Rassnick, T L Gieger, C E Kosarek, C W McFadden, M P Rosenberg |
Journal | Journal of veterinary internal medicine
(J Vet Intern Med)
2013 May-Jun
Vol. 27
Issue 3
Pg. 483-90
ISSN: 1939-1676 [Electronic] United States |
PMID | 23600734
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013 by the American College of Veterinary Internal Medicine. |
Chemical References |
- Antibiotics, Antineoplastic
- Streptozocin
|
Topics |
- Animals
- Antibiotics, Antineoplastic
(administration & dosage, adverse effects, therapeutic use)
- Dog Diseases
(drug therapy)
- Dogs
- Female
- Insulinoma
(drug therapy, veterinary)
- Male
- Streptozocin
(administration & dosage, adverse effects, therapeutic use)
|